Navigation Links
Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
Date:3/8/2011

ion), an increase of 6.2% from RMB745.4 million for the full year of 2009.

Revenue from Endu, the Company's patented anti-cancer biotech product, amounted to RMB67.9 million (US$10.3 million) in the fourth quarter of 2010, which was 11.6% of the Company's product revenue for the fourth quarter of 2010, an increase of 99.7% from RMB34.0 million for the same period in 2009. For the full year of 2010, revenue from Endu totaled RMB223.1 million (US$33.8 million), an increase of 79.6% from RMB124.2 million for the full year of 2009.

Revenue from Sinofuan, a 5-FU sustained release implant for the treatment of cancer, amounted to RMB36.1 million (US$5.5 million) for the fourth quarter of 2010, which was 6.1% of the Company's product revenue for the fourth quarter of 2010, an increase of 17.9% from RMB30.6 million for the same period in 2009. For the full year of 2010, revenue from Sinofuan totaled RMB151.8 million (US$23.0 million), an increase of 20.2% from RMB126.3 million for the full year of 2009.

Revenue from other branded generic products including Zailin and Yingtaiqingamounted to RMB255.4 million (US$38.7 million), which was 43.5% of the Company's product revenue for the fourth quarter of 2010, an increase of 20.4% from RMB212.1 million for the same period in 2009. For the full year of 2010, revenue from other branded generic products totaled RMB896.3 million (US$135.8 million), which represented an increase of 13.3% from RMB791.0 million for the full year of 2009.

Gross margin for the fourth quarter of 2010 was 84.1%, increasing from 83.6% for the same period in 2009. For the full year of 2010, gross margin was 84.0%, increasing from 82.7% for the full year of 2009.  

Research and development expenses for the fourth quarter of 2010 totaled RMB31.4 million (US$4.8 million), which represented a decrease of 37.3
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
2. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
3. Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
4. Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
5. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
6. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
7. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
8. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
9. Simceres Diosmectite API Passes EU-GMP Inspection
10. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
11. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)...  Amgen (NASDAQ: AMGN ) today announced that it will ... Tuesday, Jan. 27, 2015, after the close of the U.S. financial ... the investment community at 2 p.m. PT. Participating in the call ... chief executive officer, and other members of Amgen,s senior management team. ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical ... 2019" report to their offering. ... techniques for the detection of infectious diseases. The ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a ... reported its second quarter 2011 financial results for the period ended ... the second quarter. Updates since the beginning of ... Multiple Sclerosis (MS) ...
... Aug. 15, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: ... and seller of medicine and drugs in the People,s ... for the quarter ended June 30, 2011. Summary financial ... Quarter Financial Highlights Revenues for ...
Cached Medicine Technology:Adeona Reports Second Quarter 2011 Financial Results 2Adeona Reports Second Quarter 2011 Financial Results 3Adeona Reports Second Quarter 2011 Financial Results 4Adeona Reports Second Quarter 2011 Financial Results 5Adeona Reports Second Quarter 2011 Financial Results 6Adeona Reports Second Quarter 2011 Financial Results 7Adeona Reports Second Quarter 2011 Financial Results 8Adeona Reports Second Quarter 2011 Financial Results 9Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 2Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 3Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 4Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 5Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 6Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 7
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... (CRT) for head and neck cancer, performing targeted swallowing ... swallowing function; however, there were no significant differences in ... nine or 12 months following treatment, according to a ... Otolaryngology Head & Neck Surgery , a JAMA ...
... , MONDAY, April 16 (HealthDay News) -- Tattoos and body ... trend in western societies, but a new study in France ... alcohol than their peers. In the study, researchers ... as they left bars and other drinking establishments. The readings ...
... , MONDAY, April 16 (HealthDay News) -- New long-term research ... in heart arteries. Reporting in the April 16 issue ... study has shown the biodegradable Igaki-Tamai stent, made of a ... foreign material in an artery and reducing the occurrence of ...
... (HealthDay News) -- Media multitasking -- the use of more ... time -- may have some positive effects, a new study ... -- which is especially common in young people and could ... games or social networking -- have received widespread publicity. ...
... 16, 2012) Columbia University Medical Center (CUMC) scientists ... (PI3K) gamma and delta play a key role ... a highly aggressive childhood leukemia that is difficult to ... gamma/delta inhibitor can significantly prolong survival in a mouse ...
... should be possible to significantly improve the response of ... at Cold Spring Harbor Laboratory (CSHL), by introducing agents ... immediate surroundings, called the tumor microenvironment. In research ... , CSHL Assistant Professor Mikala Egeblad and her team ...
Cached Medicine News:Health News:Swallowing exercises linked with short-term improvement among patients with head and neck cancer 2Health News:Tattoos, Piercings Tied to Heavier Drinking in French Study 2Health News:Dissolvable Heart Artery Stents Appear Safe in Study 2Health News:Media Multitasking Might Have Mental Upside 2Health News:Study identifies potential treatment for lethal childhood leukemia 2Health News:Study identifies potential treatment for lethal childhood leukemia 3Health News:Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment 2Health News:Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment 3
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Blunt tipped forceps with a smooth, pliable silicone coating on the entire interior surface of the tip. For removal of foreign bodies or atraumatic tissue grasping....
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: